13D Filing: Biotime Inc and Asterias Biotherapeutics Inc.

 

ITEM
5. INTEREST IN SECURITIES OF THE ISSUER

 

(a)
As of the date of this Amendment No. 5, the Reporting Person beneficially owns 21,747,569 Series A Shares representing approximately
44.4% of the outstanding Series A Shares based on the number of outstanding Series A Shares reported by the Company in its Annual
Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 28, 2017.

 

(b)
As of the date of this Amendment No. 5, the Reporting Person has sole power to vote or to direct the vote of, and sole power to
dispose or direct the disposition of, the Series A Shares it beneficially owns.

 

(c)
The Reporting Person has not acquired or disposed of any Series A Shares during the past sixty days and is filing this Amendment
No. 5 to report the reduction in its percentage ownership of the outstanding Series A Shares resulting from the issuance of additional
Series A Shares by the Company.

 

(d)
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from
the sale of, the Series A Shares beneficially owned by the Reporting Person.

 

(e)
Not applicable.

 

ITEM
6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities
of the Issuer.

 

There
has been no material change from the information last reported in the Schedule 13D.

ITEM
7. MATERIAL TO BE FILED AS EXHIBITS.

 

None